Viability and drug sensitivity of M. Leprae isolated from long-term WHO/MDT treated multibacillary leprosy patients

Leprosy Review

Volumn 70, Issue 1, 1999, Pages 43-46

  Habtemariam, Haileselassie ^a  

^a All Africa Leprosy Tuberculosis and Rehabilitation Training Centre Addis Ababa   (Ethiopia)

Author keywords

[No Author keywords available]

Indexed keywords

CLOFAZIMINE; DAPSONE; LEPROSTATIC AGENT; RIFAMPICIN;

ARTICLE; CLINICAL ARTICLE; DRUG SENSITIVITY; ETHIOPIA; HUMAN; LEPROSY; LEPROSY CONTROL; MYCOBACTERIUM LEPRAE; PATIENT COMPLIANCE; SELF MEDICATION;

EID: 0032930739     PISSN: 03057518     EISSN: None     Source Type: Journal    
DOI: 10.5935/0305-7518.19990009     Document Type: Article

References (6)

1. Results of a trial in Malawi. Are 18 doses of WHO/MDT sufficient for multibacillary leprosy? Int J Lepr Other Mycobacterial Dis, 1995; 63: 1-7.
2. Shepard CC, Levy L, Fasal P. Rapid bactericidal effect of rifampicin on Mycobacterium leprae. Am J Trop Med Hyg, 1972; 21: 446-449.
3. Shepard CC, Levy L, Fasal P. Further experience with the rapid bactericidal effect of rifampicin on M. leprae. Am J Trop Med Hyg, 1974; 23: 1129-1134.
4. Collaborative effort of the US Leprosy Panel (U.S.-Japan Co-operative Medical Science Programme) rifampicin therapy of lepromatous leprosy. Am J Trop Med Hyg, 1975; 475-484.
5. Levy L, Shepard CC, Fasal P. The bactericidal effect of rifampicin on M. leprae in man. a) Single doses of 600, 900 and 1200 and b) daily doses of 300 mg. Int J Lepr, 1976; 44: 183-187.
6. Habtemariam HS, Guebre-Xaber M. Lack of viability of Mycobacterium leprae isolated from nasal secretions of lepromatous leprosy patients following daily rifampicin and DDS therapy. Lepr Rev, 1993; 64: 312-315.